Evogene Ltd. (EVGN)

0,6300 +0,0250 (+4,13%) Börsenschluss: 04:00PM EDT

Evogene Ltd.

13 Gad Feinstein Street
Park Rehovot PO Box 4173
Rehovot 7414002
Israel
972 8 931 1900
https://www.evogene.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ofer Haviv CPA	CEO & Pres	472k	N/A	1966
Mr. Mark Kapel	Chief Technology Officer	295k	N/A	1977
Dr. Elran Hillel Haber M.B.A., Ph.D.	Chief Exec. Officer of Biomica Ltd	287k	N/A	1980
Mr. Yaron Eldad	Chief Financial Officer	N/A	N/A	1965
Mr. Sassi Masliah	Exec. VP of Corp. Devel.	N/A	N/A	1979
Ms. Liat Foigel Wejgman	VP of HR	N/A	N/A	N/A
Dr. Nir Arbel	Chief Product Officer	N/A	N/A	1980
Mr. Eyal Ronen	Exec. VP of Bus. Devel.	N/A	N/A	N/A
Dr. Brian Ember	Chief Exec. Officer of AgPlenus Ltd	N/A	N/A	1976
Mr. Russ Putland	VP of Commercial of Lavie Bio Ltd.	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Corporate Governance

Evogene Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.